Drug Clinical Trial Institution, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou 510060, China.
Department of Pharmacy, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen 518107, China.
Eur J Pharmacol. 2018 Aug 5;832:138-144. doi: 10.1016/j.ejphar.2018.05.017. Epub 2018 May 18.
Mesangial proliferative glomerulonephritis (MsPGN) is characterized by glomerular mesangial cells proliferation and extracellular matrix deposition in mesangial area, which develop into glomerulosclerosis. Both silent information regulator 2-related protein 1 (Sirt1) and nuclear factor erythroid 2-related factor 2/anti-oxidant response element (Nrf2/ARE) pathway had remarkable renoprotective effects. However, whether Sirt1 and Nrf2/ARE pathway can regulate the pathological process of MsPGN remains unknown. Here, we found that Sirt1 activation by SRT1720 decreased mesangial hypercellularity and mesangial matrix areas, reduced renal Col4 and α-SMA expressions, lowered 24 h proteinuria, and eventually reduced FN and TGF-β1 expressions in rats received anti-Thy 1.1 IgG. Further study showed that SRT1720 markedly enhanced the activity of Nrf2/ARE pathway including promoting the nuclear content and ARE-binding ability of Nrf2, elevating the protein levels of HO-1 and SOD1, two target genes of Nrf2, which eventually increased total SOD activity and decreased malondialdehyde level in the kidney tissues of experimental anti-Thy 1.1 MsPGN rats. Taken together, Sirt1 prevented the pathological process of experimental anti-Thy 1.1 MsPGN through promoting the activation of Nrf2/ARE pathway, which warrants further elucidation. Sirt1 might be a potential therapeutic target for treating MsPGN.
系膜增生性肾小球肾炎(MsPGN)的特征是肾小球系膜细胞增生和细胞外基质在系膜区沉积,进而发展为肾小球硬化。沉默信息调节因子 2 相关蛋白 1(Sirt1)和核因子红细胞 2 相关因子 2/抗氧化反应元件(Nrf2/ARE)通路均具有显著的肾脏保护作用。然而,Sirt1 和 Nrf2/ARE 通路是否能调节 MsPGN 的病理过程尚不清楚。在这里,我们发现 Sirt1 的激活剂 SRT1720 可减少系膜细胞增生和系膜基质面积,降低肾脏 Col4 和 α-SMA 的表达,降低抗-Thy 1.1 IgG 诱导的大鼠 24 小时蛋白尿,并最终降低 FN 和 TGF-β1 的表达。进一步的研究表明,SRT1720 显著增强了 Nrf2/ARE 通路的活性,包括促进 Nrf2 的核内容物和 ARE 结合能力,提高 Nrf2 的两个靶基因 HO-1 和 SOD1 的蛋白水平,最终增加总 SOD 活性并降低肾脏组织中丙二醛的水平在实验性抗-Thy 1.1 MsPGN 大鼠中。总之,Sirt1 通过促进 Nrf2/ARE 通路的激活来防止实验性抗-Thy 1.1 MsPGN 的病理过程,这值得进一步研究。Sirt1 可能是治疗 MsPGN 的潜在治疗靶点。